January 2025, Vol 2, No 1
As the calendar turns and another year begins, it’s important to take a minute and reflect on the year gone by and what’s ahead. Read More ›
Healthcare deserts are regions in the United States with limited access to healthcare providers and medicine, often contributing to poor health outcomes and healthcare inequities for residents of these communities. Read More ›
On October 29, 2024, the Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) made some recommendations that are going to change the way immunization schedules look for 2025, particularly as they relate to pneumococcal disease and COVID-19 Read More ›
At least one base pharmacy will be investigating ways to engage military personnel who don’t use the pharmacy, after a survey underscored some key barriers to pharmacy access. Read More ›
In recognition of Veterans Day, Amplity Health launched ImPACT Federal Health, a new publication dedicated to supporting Patient-Aligned Care Teams (PACTs) in removing barriers to care for military and Veterans Administration (VA) patients, at the Joint Federal Pharmacy Seminar (JFPS). Read More ›
The approval makes concizumab the second anti-TFPI antibody available in the United States, following the approval of marstacimab-hncq (Hympavzi; Pfizer) in October 2024 for hemophilia A or B without inhibitors. Read More ›
The FDA has approved ustekinumab-stba (Steqeyma; Celltrion) for subcutaneous injection or intravenous infusion in adult and pediatric patients with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn’s disease and ulcerative colitis. Read More ›
Olezarsen (Tryngolza; Ionis) has been approved by the FDA for the treatment of familial chylomicronemia syndrome (FCS), a rare, inherited disorder characterized by severe hypertriglyceridemia. Read More ›
The FDA has approved the expanded use of elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta; Vertex) for the treatment of people with cystic fibrosis (CF) ≥2 who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to the treatment based on clinical and/or in vitro data. Read More ›
Officials with the FDA issued Zealand Pharma a response letter saying that the application did not meet the full requirements for substantial evidence to establish the efficacy and safety of the to-be-marketed dose of glepaglutide for the treatment of short bowel syndrome in adults with intestinal failure. Read More ›